Madrigal Pharmaceuticals takes a major step toward improving the lives of patients with NASH with the help of the PRO-C3 biomarker
Madrigal met both primary endpoints in the Phase 3 MAESTRO-NASH clinical trial of Resmetirom
We would like to congratulate Madrigal Pharmaceuticals for taking a major step toward improving the lives of patients with NASH.
Madrigal met both primary endpoints (NASH resolution and fibrosis stage improvement) in the Phase 3 MAESTRO-NASH clinical trial of Resmetirom for the treatment of NASH and liver fibrosis. This is a great testament to the hard work of the Madrigal team.
In a previous Phase 2 NASH clinical trial, Madrigal Pharmaceuticals showed that Resmetirom treatment significantly reduced levels of PRO-C3, suggesting that Resmetirom reduces the formation of collagen type III.
These findings are consistent with the current results of the MAESTRO-NASH clinical trial, which showed that treatment with Resmetirom leads to both NASH resolution and improvement in liver fibrosis.
Nordic Bioscience is pleased to have also supported the MAESTRO-NASH clinical trial with our biomarker for collagen type III formation (PRO-C3) and is eager to see the results!
